The FDA is planning new rules that may impact the development and approval of drugs. Some reports suggest the rules aim to speed up clinical trials, while others indicate the agency may be reining in certain aspects of the process, such as drug ads. The specifics and potential effects of the proposed changes are unclear, with some outlets focusing on expedited development and others on reforms or changes in leadership and policy direction.